Thus, our data indicate that anti–PD-1–mediated immune selection depletes tumor cells lacking NANOG while enriching tumor cells that express NANOG, suggesting that NANOG expression in tumor cells could confer a survival advantage under the immune selection pressure imposed by anti–PD-1 therapy. This evidence concerns the gene PDCD1 and neoplasm.